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A protein activator of glucosylceramidase (EC 3.2.1.45) has been previously identified by us in human pla- 
centa [(1985) B&him. Biophys. Acta 836, 157-1661. In the present paper we report that its function in vitro 
is to stimulate the binding of the enzyme to its substrate, glucosylceramide. After the purification step which 
frees the enzyme of most of its activator protein (octyl-Sepharose 4B chromatography), the capacity of 
glucosylceramidase to bind to the glucosylceramide micelles is dramatically decreased. The addition of the 
activator protein to the purified enzyme restores this binding. 
Protein activator; Glucosylceramidase; Gaucher’s disease 
1. INTRODUCTION 
Glucosylceramide is hydrolyzed into glucose and 
ceramide by glucosylceramidase (EC 3.2.1.45), a 
membrane-bound, lysosomal enzyme [ 11, which 
displays a markedly reduced activity in Gaucher 
disease [2,3]. 
The catabolism of several glycosphingolipids re- 
quires special proteins, known as natural activator 
proteins or sphingolipid activator proteins (SAP) 
[4-61. We have recently identified in human 
placenta such an activator protein (‘placental fac- 
tor’) which enhances several-fold the enzymatic 
hydrolysis of glucosylceramide and is present in 
large excess over the glucosylceramidase in the 
tissue [7]. A comparison between a previously 
reported glucosylceramidase activator, the 
‘Gaucher factor’ [8-l 11, and the placental factor 
indicates that they are different substances [12]; 
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the former is mainly active in the hydrolysis of 
4-methylumbelliferyl-b-D-glucopyranoside, while 
the latter is specifically effective for that of 
glucosylceramide. 
Here, we have investigated the possible 
mechanism of the placental factor in the activation 
of the enzymatic hydrolysis of glucosylceramide. 
2. MATERIALS AND METHODS 
2.1. Materials 
Glucosylceramide purified from spleen of pa- 
tients with Gaucher disease was labelled with 
tritium in the glucose moiety according to 
McMaster and Radin [13]. Sodium taurocholate 
(synthetic, 98% pure), oleic acid, trypsin inhibitor 
from soybean, bovine serum albumin, ovalbumin 
and bovine thyroglobulin were from Sigma (St. 
Louis, MO). [i4C]Taurocholate (55 mCi/mmol) 
and [l-14C]oleic acid (56 mCi/mmol) were from 
Amersham International (England). Other chemi- 
cals and reagents were from standard commercial 
sources. 
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2.2. Glucosylceramidase and placental factor 
preparations 
Glucosylceramidase was purified from placenta 
as in our previous paper [7] for preparation II. In 
the present work we have used the enzyme at two 
different steps of purification: the butanol extrac- 
tion (prep B.E.) and the octyl-Sepharose 4B 
chromatography (prep II itself). The placental fac- 
tor was prepared as in [7]. 
2.3. Glucosylceramidase assay 
The standard assay mixture contained, in a final 
volume of 0.2 ml, 40 pg [3H]glucosylceramide 
(2600 dpm/nmol), 0.25 mg sodium taurocholate, 
5Opg oleic acid, 0.1-0.2 mol/l sodium citrate- 
phosphate buffer, pH 5.6 (buffer A), and an ap- 
propriate amount of enzyme source. The reaction 
time was 1 h at 37°C. The enzymatically released 
glucose was estimated as described [7]. When pre- 
sent the placental factor was added to the assay 
mixture immediately before starting the enzymatic 
reaction. One unit of glucosylceramidase is defined 
as the amount of enzyme which hydrolyzes 1 nmol 
glucosylceramide/h under the standard assay con- 
ditions. 
2.4. Glucosylceramide micelle preparation and its 
interaction with glucosylceramidase 
2004 of 0.2-0.4 mol/l sodium citrate- 
phosphate buffer (pH 5.6) was added to a dried 
mixture of 16Opg glucosylceramide, 1 mg tauro- 
cholate and 200 pug oleic acid. After sonication for 
30 s at 4°C under a stream of nitrogen (Branson B 
15 sonifier, equipped with a 3 mm microtip) the 
lipid micelles were left overnight at room 
temperature. A solution of 70 pug trypsin inhibitor 
in 200 ~1 water was then added. When required the 
latter solution also contained the enzyme source 
with or without the placental factor. After 5 min at 
37°C under agitation, the samples were mixed with 
400 ~1 of 20% (w/v) sucrose in buffer A and kept 
in ice for 15 min before centrifugation. 
2.5. Sucrose density gradient ten trifugation 
Discontinuous sucrose density gradients were 
prepared by manually layering the following solu- 
tions into Ultra-clearTM centrifuge tubes 
(14 x 89 mm): 5.8 ml of 50% (w/v) sucrose in buf- 
fer A, the lipid micelle suspension prepared as 
described above (0.8 ml, 10% (w/v) sucrose), 5 ml 
of 5% (w/v) sucrose in buffer A, and 0.4 ml buffer 
A. The top buffer A layer contained additionally 
2 mg sodium taurocholate. The presence of 
detergent in the upper layer was necessary to main- 
tain the floating lipids in a dispersed form; without 
taurocholate in the upper layer the recovery of 
glucosylceramide and oleic acid was very poor. 
Centrifugation was performed in a Beckman SW 
41 Ti rotor for 15 min at 40000 rpm at 4°C. Frac- 
tions of 1 ml were pumped out at a flow rate of 
0.5 ml/min through a long needle carefully in- 
serted down to the bottom of the centrifuge tube. 
The last 1 ml was left in the tube to rinse the lipid 
film of the meniscus remaining in part attached to 
the wall of the tube during gradient fractionation. 
2.6. Determination of protein 
Protein was determined by the dye-binding 
method of Bradford [14] with bovine serum 
albumin as standard. 
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Fig. 1. Discontinuous density gradient centrifugation of 
the glucosylceramide micelles. Two identical samples 
containing glucosylceramide, taurocholate, oleic acid 
and trypsin inhibitor, were prepared and centrifuged as 
reported in section 2. One sample was supplemented 
with 79 nCi [3H]glucosylceramide and 80 nCi 
[14C]taurocholate, the other with 79 nCi [‘4C]oleic acid. 
The glucosylceramide (o), taurocholate (0) and oleic 
acid (A) content of the fractions was determined by their 
3H and 14C radioactivity measured on aliquots of 200 pl. 
The protein content was tested on aliquots of 100~1 
(0). 
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3. RESULTS AND DISCUSSION 
When the lipid micelle suspension, containing 
glucosylceramide, oleic acid and taurocholate at 
the same ratios as in the glucosylceramidase assay, 
was layered in the middle of the discontinuous 
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sucrose density gradient and centrifuged, glucosyl- 
ceramide and oleic acid moved to the upper layer 
of the gradient, while taurocholate remained at the 
starting position together with the trypsin in- 
hibitor, which had been added to the sample to 
observe the behaviour of an unrelated protein 
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Fig.2. Discontinuous density gradient centrifugation of glucosylceramidase incubated with glucosylceramide micelles. 
The samples were the same as in fig.1 except for the presence of glucosylceramidase. The enzyme sources were either 
prep B.E. (A) (70 U when measured without placental factor or 85 U when measured in its presence) or prep II (B-D) 
(13 U when measured without placental factor or 85 U when measured in its presence). The placental factor was includ- 
ed in the samples of panel C (0.5 pg) and panel D (5 pg). The samples were centrifuged as in fig.1. Aliquots of 50~1 
of every fraction were tested for glucosylceramidase activity in the presence of 1 /cg/tube of placental factor (o), and 
aliquots of 100 ~1 for protein content (0). Glucosylceramide, taurocholate and oleic acid patterns after centrifugation 
were determined adding, in parallel experiments, the corresponding labelled compounds. The patterns were always iden- 
tical to that reported in fig.1 and are omitted for clarity. 
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under these ultracentrifugation conditions (fig.1). 
The same pattern was observed in the absence of 
the trypsin inhibitor. The recovery of glucosylcer- 
amide and oleic acid after centrifugation was 
75-85% and that of trypsin inhibitor and tauro- 
cholate 90- 100%. A mixture of taurocholate and 
oleic acid is commonly used to stimulate the en- 
zymatic hydrolysis of glucosylceramide [ 151. It has 
been assumed that one of the functions of tauro- 
cholate is to form mixed micelles with the lipid 
substrate [16]. Our results showed that it is not the 
case, at least under our glucosylceramidase assay 
conditions. The ease with which taurocholate and 
glucosylceramide can be separated indicates that 
they do not form mixed micelles. 
When the same ultracentrifugation procedure 
was carried out with a sample also containing a 
water-soluble preparation of glucosylceramidase 
partially purified by butanol extraction (prep 
B.E.), most of the glucosylceramidase activity 
moved to the upper part of the gradient together 
with oleic acid and glucosylceramide (fig.2A). The 
latter must be the component responsible for 
transfer of the enzyme since in its absence the 
glucosylceramidase activity remained at the sample 
layer (not shown). The capacity of glucosylcer- 
amidase to bind to its substrate was dramatically 
decreased when the enzyme was further purified by 
octyl-Sepharose chromatography. In fact, when 
the ultracentrifugation was performed using prep 
II as the enzyme source, most of the enzyme activi- 
ty was found at the starting position and only 
about 20% of it moved to the top layer (fig.2B). 
The addition of increasing amounts of placental 
factor, a protein capable of increasing 6-9-fold the 
rate of enzymatic hydrolysis of glucosylceramide 
[7], increased the percentage of the floating gluco- 
sylceramidase until almost all the enzyme activity 
was found in the top layer (fig.ZC,D). When com- 
parable amounts of other proteins such as 
albumin, ovalbumin and thyroglobulin were 
substituted for the placental factor, they did not 
promote any binding of glucosylceramidase (not 
shown). The recovery of enzyme activity was 
80-100% in all the reported experiments. 
Our previous [7] and present results indicate that 
the placental factor, which is removed from gluco- 
sylceramidase by the octyl-Sepharose chromatog- 
raphy [7], is responsible for the increase of both 
the enzymatic activity and the binding of the en- 
zyme to its substrate, most probably the first 
phenomenon being the consequence of the second. 
The best characterized mechanism by which ac- 
tivator proteins promote the hydrolysis of sphingo- 
lipids is that described for the GMz-ganglioside 
activator [17]. It extracts the ganglioside from the 
micelles to form a water-soluble activator-lipid 
complex which can interact with its hydrolysing 
water-soluble enzyme, ,&hexosaminidase A. In 
contrast, the placental factor promotes the binding 
of the glucosylceramidase to its substrate anchor- 
ing the enzyme to the glucosylceramide micelles. 
This is the first example of such an effect exerted 
by a glycosphingolipid activator protein. ” 
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